Mutation Profile of Resected EGFR‐Mutated Lung Adenocarcinoma by Next‐Generation Sequencing

Conclusion.Operable lung ADCs with EGFR TKI‐sensitizing mutations are associated with a high proportion of co‐mutations. Mutation profiling of these resected tumors could facilitate in determining the applicability and efficacy of adjuvant EGFR TKI therapeutic strategy.Implications for Practice.The efficacy of adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy for lung cancer harboring EGFR mutation after surgical resection is still under debate. Next‐generation sequencing of 416 cancer‐relevant genes in 139 resected lung cancers revealed the co‐mutational landscape with background EGFR mutation. Notably, the study identified potential EGFR TKI‐resistant mutations in 34.71% of patients with a drug‐sensitizing EGFR mutation and who were naive in terms of targeted therapy. A comprehensive mutation profiling of these resected tumors could facilitate in determining the applicability and efficacy of adjuvant EGFR TKI therapeutic strategy for these patients.

Source: The Oncologist - October 15, 2019 Category: Cancer & Oncology Authors: Ze-Rui Zhao, Yao-Bin Lin, Calvin S.H. Ng, Rong Zhang, Xue Wu, Qiuxiang Ou, Wendan Chen, Wen-Jie Zhou, Yong-Bin Lin, Xiao-Dong Su, Yang W. Shao, Hao Long Tags: Lung Cancer Source Type: research